1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,266 | 0,334 | 22.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | Sprint Bioscience AB: Sprint Bioscience Receives Funding from Vinnova | 330 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ), together with MAX IV, has been awarded approximately SEK 940,000 in funding from Vinnova for a joint research initiative focused on alternative methods for fragment screening... ► Artikel lesen | |
| 26.08. | Sprint Bioscience AB Q2 Loss Increases | 1 | RTTNews | ||
| 23.07. | Sprint Bioscience AB: Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development | 367 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announced that it has entered into an agreement with Lilly TuneLab, a collaborative AI-driven drug discovery platform created by Eli Lilly and Company (Lilly). By joining... ► Artikel lesen | |
| 13.05. | Sprint Bioscience AB Q1 Loss Widens | 1 | RTTNews | ||
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 16.04. | Sprint Bioscience AB: Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication | 320 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces the conclusion of a targeted evaluation of the STK25 program, conducted in partnership with the Experimental Drug Development Centre (EDDC), Singapore's national... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Sprint Bioscience appoints Jenni Björnulfson as CFO | 255 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces that Jenni Björnulfson has been appointed chief Financial Officer (CFO) of the company. With extensive and diverse experience in both life science and finance... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Positive results expand the NNMT program into Chronic Kidney Disease | 283 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from its NNMT program from a proof-of-concept study demonstrating therapeutic potential in Chronic Kidney Disease (CKD). Based on these findings... ► Artikel lesen | |
| 17.03. | Sprint Bioscience AB: Sprint Bioscience reports positive results from the VRK1 program | 387 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from a pre-clinical proof-of-concept (POC) study performed within the company's VRK1 program. The results show that VRK1 inhibition selectively... ► Artikel lesen | |
| 24.11.25 | Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences | 1.107 | AFX News | FOSTER CITY (dpa-AFX) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 5,510 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,400 | +0,75 % | Cosciens Biopharma Inc (2): Cosciens raises $12M of up to $20M debenture deal | ||
| HALOZYME THERAPEUTICS | 110,25 | -0,72 % | H.C. Wainwright reiterates Halozyme stock rating on Takeda trial data | ||
| ABCELLERA BIOLOGICS | 10,080 | -0,59 % | AbCellera Biologics Inc.: AbCellera to Present at Upcoming Investor Conferences in November 2026 | AbCellera (Nasdaq: ABCL) announced thatthe Company will present at the following investor conferences:
Stifel Healthcare Conference, November 11, 2026
Jefferies Global Healthcare Conference... ► Artikel lesen | |
| GLOW LIFETECH | 0,015 | -3,33 % | Smallcap Discoveries: Glow Lifetech Corp. to Present at the Annual Smallcap Discoveries Conference in Vancouver | Toronto, Ontario--(Newsfile Corp. - September 24, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it will be participating in... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 316,80 | -2,28 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 1,770 | 0,00 % | BioLineRx Ltd.: BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September -
- Announced new data... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,016 | -4,55 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences | BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 2,880 | -0,69 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026
Cash, cash equivalents and short-term... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 9,149 | -8,56 % | CMBI Raises INNOVENT BIO TP to HKD138.63, IBI3003 Clinical Data Validate Leadership in MM TCE Field | ||
| OVID THERAPEUTICS | 2,160 | +3,85 % | Ovid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results | First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA... ► Artikel lesen | |
| GEOVAX LABS | 0,216 | 0,00 % | EQS-News: GeoVax, Inc.: GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 06.10.2026 / 14:37... ► Artikel lesen | |
| COCRYSTAL | 0,805 | -1,23 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 6,070 | +0,66 % | Precision BioSciences stellt auf H.C. Wainwright Konferenz Zwei-Säulen-Strategie vor |
Das Unternehmen SPRINT BIOSCIENCE AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,303 Euro und damit +4,12 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.